Qiagen N.V. (NYSE:QGEN) Receives Average Rating of "Hold" from Analysts

Key Points

• Shares of Qiagen carry a consensus analyst rating of Hold from 11 firms (1 sell, 6 hold, 4 buy) with an average 12‑month price target of $53.64.
• Qiagen beat Q1 estimates (EPS $0.62 vs. $0.61; revenue $540.4M vs. $528.5M) but issued weaker Q2 and full‑year 2026 guidance below Street expectations, creating near‑term downward pressure on the stock.
• A shareholder investigation into company executives was announced, raising legal/uncertainty risk that could amplify selling pressure.

Shares of Qiagen N.V. (NYSE:QGEN - Get Free Report) have received a consensus rating of "Hold" from the eleven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $53.6433.

A number of analysts have recently commented on QGEN shares. Zacks Research lowered shares of Qiagen from a "hold" rating to a "strong sell" rating in a research report on Monday, March 9th. Wall Street Zen lowered shares of Qiagen from a "buy" rating to a "hold" rating in a research report on Saturday, March 28th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the stock a "hold" rating in a research report on Friday, February 6th. Barclays set a $44.00 price objective on shares of Qiagen and gave the stock an "equal weight" rating in a research report on Tuesday, April 14th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Qiagen in a research report on Friday, March 27th.

Qiagen Stock Performance

Shares of NYSE:QGEN opened at $33.98 on Wednesday. The company has a market capitalization of $7.00 billion, a price-to-earnings ratio of 16.85, a P/E/G ratio of 1.97 and a beta of 0.79. The firm's 50 day simple moving average is $42.37 and its 200 day simple moving average is $46.95. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. Qiagen has a fifty-two week low of $33.78 and a fifty-two week high of $57.81.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating analysts' consensus estimates of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. Qiagen's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the company posted $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, sell-side analysts forecast that Qiagen will post 2.5 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Danske Bank A S bought a new position in Qiagen during the third quarter worth $36,000. Smartleaf Asset Management LLC boosted its position in shares of Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company's stock valued at $39,000 after acquiring an additional 830 shares during the period. Manchester Capital Management LLC bought a new stake in shares of Qiagen in the fourth quarter valued at about $42,000. Global Retirement Partners LLC boosted its position in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company's stock valued at $52,000 after acquiring an additional 851 shares during the period. Finally, Allworth Financial LP boosted its position in shares of Qiagen by 23.2% in the third quarter. Allworth Financial LP now owns 1,358 shares of the company's stock valued at $61,000 after acquiring an additional 256 shares during the period. 70.00% of the stock is owned by institutional investors.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Preliminary Q1 results met adjusted diluted EPS outlook and reported net sales of about $492M (+2% reported), supporting near‑term profitability despite mixed sales trends. QIAGEN reports preliminary Q1 2026 results
• Neutral Sentiment: Unusually large options activity: traders bought ~6,107 call contracts on Monday (about +176% vs. average), indicating heightened speculative interest or hedging that can amplify intraday moves.
• Neutral Sentiment: Full Q1 earnings call transcript provides detail on end‑market weakness (lower QuantiFERON demand, cautious U.S. Life Sciences customers) and management’s rationale for the outlook. Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/industry writeups that deep‑dive into Q1 metrics are circulating; they summarize mixed product trends and longer‑term implications but do not add new company disclosures. Qiagen’s Q1 2026 Earnings Report: A Deep Dive into Financial Performance and Market Trends
• Negative Sentiment: Guidance cut: Q2 EPS guided to ~0.60 (street ~0.62) and Q2 revenue to ~$523.3M (street ~$554M). Full‑year 2026 EPS guided to ~2.43 (street ~2.51) and revenue to ~$2.1B (street ~$2.2B). These misses are the primary near‑term driver of downward pressure on the stock.
• Negative Sentiment: Shareholder investigation announced: law firm Johnson Fistel is investigating potential claims against Qiagen executives, which raises legal/uncertainty risk and can increase selling pressure. Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel

Qiagen Company Profile

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.